Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study

Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study

Abstract Background A majority of patients undergoing curative intent surgery for pancreatic ductal adenocarcinoma (PDAC) will unfortunately develop recurrent disease. Treatment outcomes for patients with metastatic disease remain suboptimal. In this study, we evaluated clinical outcomes of patients...

Full description

Bibliographic Details
Main Authors: Laura Miotke, Christopher Nevala-Plagemann, Jian Ying, Vaia Florou, Benjamin Haaland, Ignacio Garrido-Laguna
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Cancer
Subjects:
Real-world outcomes
Overall survival
Pancreatic ductal adenocarcinoma
Recurrent
De Novo
Online Access:https://doi.org/10.1186/s12885-022-10130-4

Internet

https://doi.org/10.1186/s12885-022-10130-4

Similar Items